Cargando…

Targeting DYRK1B suppresses the proliferation and migration of liposarcoma cells

Liposarcoma is a common subtype of soft tissue sarcoma and accounts for 20% of all sarcomas. Conventional chemotherapeutic agents have limited efficacy in liposarcoma patients. Expression and activation of serine/threonine-protein kinase dual-specificity tyrosine-(Y)-phosphorylation regulated kinase...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Hua, Shen, Jacson, Choy, Edwin, Hornicek, Francis J., Shan, Aijun, Duan, Zhenfeng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5862568/ https://www.ncbi.nlm.nih.gov/pubmed/29568347 http://dx.doi.org/10.18632/oncotarget.22743

Ejemplares similares

Targeting EZH2-mediated methylation of H3K27 inhibits proliferation and migration of Synovial Sarcoma in vitro
por: Shen, Jacson K., et al.
Publicado: (2016)

Pharmacokinetics and tolerability of NSC23925b, a novel P-glycoprotein inhibitor: preclinical study in mice and rats
por: Gao, Yan, et al.
Publicado: (2016)

Targeting programmed cell death ligand 1 by CRISPR/Cas9 in osteosarcoma cells
por: Liao, Yunfei, et al.
Publicado: (2017)

miR‐15b modulates multidrug resistance in human osteosarcoma in vitro and in vivo
por: Duan, Zhenfeng, et al.
Publicado: (2016)

Transcriptional activation of CBFβ by CDK11(p110) is necessary to promote osteosarcoma cell proliferation
por: Feng, Yong, et al.
Publicado: (2019)

Correction to: Transcriptional activation of CBFβ by CDK11(p110) is necessary to promote osteosarcoma cell proliferation
por: Feng, Yong, et al.
Publicado: (2019)

Synergistic Effects of Targeted PI3K Signaling Inhibition and Chemotherapy in Liposarcoma
por: Guo, Shang, et al.
Publicado: (2014)

Androgen receptor is a potential novel prognostic marker and oncogenic target in osteosarcoma with dependence on CDK11
por: Liao, Yunfei, et al.
Publicado: (2017)

Expression of programmed cell death ligand 1 (PD-L1) and prevalence of tumor-infiltrating lymphocytes (TILs) in chordoma
por: Feng, Yong, et al.
Publicado: (2015)

Author Correction: Androgen receptor is a potential novel prognostic marker and oncogenic target in osteosarcoma with dependence on CDK11
por: Liao, Yunfei, et al.
Publicado: (2018)

NSC23925, Identified in a High-Throughput Cell-Based Screen, Reverses Multidrug Resistance
por: Duan, Zhenfeng, et al.
Publicado: (2009)

CD44 is a direct target of miR-199a-3p and contributes to aggressive progression in osteosarcoma
por: Gao, Yan, et al.
Publicado: (2015)

The emerging roles and therapeutic potential of cyclin-dependent kinase 11 (CDK11) in human cancer
por: Zhou, Yubing, et al.
Publicado: (2016)

Noncoding RNA in drug resistant sarcoma
por: Li, Xiaoyang, et al.
Publicado: (2017)

Wnt inhibitory factor 1 (WIF1) methylation and its association with clinical prognosis in patients with chondrosarcoma
por: Liu, Pei, et al.
Publicado: (2017)

A-770041 reverses paclitaxel and doxorubicin resistance in osteosarcoma cells
por: Duan, Zhenfeng, et al.
Publicado: (2014)

MicroRNA-155 expression is independently predictive of outcome in chordoma
por: Osaka, Eiji, et al.
Publicado: (2015)

Rhabdomyosarcoma: Advances in Molecular and Cellular Biology
por: Sun, Xin, et al.
Publicado: (2015)

Overexpression of EZH2 is associated with the poor prognosis in osteosarcoma and function analysis indicates a therapeutic potential
por: Sun, Ranran, et al.
Publicado: (2016)

Genotyping Cancer-Associated Genes in Chordoma Identifies Mutations in Oncogenes and Areas of Chromosomal Loss Involving CDKN2A, PTEN, and SMARCB1
por: Choy, Edwin, et al.
Publicado: (2014)

MDR1 siRNA loaded hyaluronic acid-based CD44 targeted nanoparticle systems circumvent paclitaxel resistance in ovarian cancer
por: Yang, Xiaoqian, et al.
Publicado: (2015)

Targeting ABCB1 (MDR1) in multi-drug resistant osteosarcoma cells using the CRISPR-Cas9 system to reverse drug resistance
por: Liu, Tang, et al.
Publicado: (2016)

Oleanane triterpenoid CDDO-Me induces apoptosis in multidrug resistant osteosarcoma cells through inhibition of Stat3 pathway
por: Ryu, Keinosuke, et al.
Publicado: (2010)

ZNF93 Increases Resistance to ET-743 (Trabectedin; Yondelis®) and PM00104 (Zalypsis®) in Human Cancer Cell Lines
por: Duan, Zhenfeng, et al.
Publicado: (2009)

Up-regulation of CD44 in the development of metastasis, recurrence and drug resistance of ovarian cancer
por: Gao, Yan, et al.
Publicado: (2015)

Potentials of Long Noncoding RNAs (LncRNAs) in Sarcoma: From Biomarkers to Therapeutic Targets
por: Min, Li, et al.
Publicado: (2017)

Decrease of miR-622 expression suppresses migration and invasion by targeting regulation of DYRK2 in colorectal cancer cells
por: Wang, Yong, et al.
Publicado: (2017)

Cyclin-dependent kinase 9 (CDK9) is a novel prognostic marker and therapeutic target in osteosarcoma
por: Ma, Hangzhan, et al.
Publicado: (2018)

MicroRNA Involvement in Osteosarcoma
por: Kobayashi, Eisuke, et al.
Publicado: (2012)

Inhibition of ABCB1 (MDR1) Expression by an siRNA Nanoparticulate Delivery System to Overcome Drug Resistance in Osteosarcoma
por: Susa, Michiro, et al.
Publicado: (2010)

Cyclin-dependent kinase 7 (CDK7) is an emerging prognostic biomarker and therapeutic target in osteosarcoma
por: Ma, Hangzhan, et al.
Publicado: (2021)

Effectiveness of tumor‑treating fields to reduce the proliferation and migration of liposarcoma cell lines
por: Lee, Won Seok, et al.
Publicado: (2023)

Inhibition of DYRK1A and GSK3B induces human β-cell proliferation
por: Shen, Weijun, et al.
Publicado: (2015)

T‐LAK cell‐originated protein kinase (TOPK) is a Novel Prognostic and Therapeutic Target in Chordoma
por: Thanindratarn, Pichaya, et al.
Publicado: (2020)

DCAF7/WDR68 is required for normal levels of DYRK1A and DYRK1B
por: Yousefelahiyeh, Mina, et al.
Publicado: (2018)

Differential maturation and chaperone dependence of the paralogous protein kinases DYRK1A and DYRK1B
por: Papenfuss, Marco, et al.
Publicado: (2022)

Tissue Microarray Immunohistochemical Detection of Brachyury Is Not a Prognostic Indicator in Chordoma
por: Zhang, Linlin, et al.
Publicado: (2013)

DYRK1A activates NFATC1 to increase glioblastoma migration
por: Liu, Heng, et al.
Publicado: (2021)

Aberrant CDK9 expression within chordoma tissues and the therapeutic potential of a selective CDK9 inhibitor LDC000067
por: Shen, Shen, et al.
Publicado: (2020)

Inhibition of DYRK1A Stimulates Human β-Cell Proliferation
por: Dirice, Ercument, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_77mr55h8ub5s3n89bkimdd6k8t